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The effects of pharmaceuticals and personal care products (PPCPs) on aquatic 18 
organisms represent a significant current concern. Herein, a targeted 19 
metabolomics approach using liquid chromatography-high resolution mass 20 
spectrometry (LC-HRMS) is presented to characterise concentration changes in 21 
29 selected metabolites following exposures of aquatic invertebrates, 22 
Gammarus pulex, to pharmaceuticals. Method performance revealed excellent 23 
linearity (R2>0.99), precision (0.1-19 %) and lower limits of detection (0.002-24 
0.20 ng) for all metabolites studied. Three pharmaceuticals were selected 25 
representing the low, middle and high range of measured acute measured 26 
toxicities (of a total of 26 compounds). Gammarids were exposed to both the 27 
no-observed-adverse-effect-level (NOAEL) and the lowest-observed-adverse-28 
effect-level (LOAEL) of triclosan (0.1 and 0.3 mg L-1), nimesulide (0.5 and 1.4 29 
mg L-1) and propranolol (100 and 153 mg L-1) over 24 hrs. Quantitative 30 
metabolite profiling was then performed. Significant changes in metabolite 31 
concentrations relative to controls are presented and display distinct clustered 32 
trends for each pharmaceutical. Approximately 37 % (triclosan), 33 % 33 
(nimesulide) and 46 % (propranolol) of metabolites showed statistically 34 
significant time-related effects. Observed changes are also discussed with 35 
respect to internal concentrations of the three pharmaceuticals measured using 36 
a method based on pulverised liquid extraction, solid phase extraction and LC-37 
MS/MS. Potential metabolic pathways that may be affected by such exposures 38 
are also discussed. This represents the first study focussing on quantitative, 39 
targeted metabolomics of this lower trophic level benthic invertebrate that may 40 
elucidate biomarkers for future risk assessment.   41 
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1. Introduction 46 
 In the last decade, pharmaceuticals have been recognised as an emerging 47 
class of environmental contaminants and their fate, occurrence and 48 
physicochemical behaviour in the aquatic environment have been extensively 49 
studied and reviewed (Daughton and Ternes 1999; Evgenidou et al., 2015; 50 
Monteiro and Boxall 2010). The ecotoxicological consequences of incomplete 51 
removal of pharmaceuticals or their metabolites in wastewater or drinking water 52 
treatment plants (WWTP/DWTP) are a matter of current environmental concern 53 
which still requires further research (Gómez-Canela et al., 2013). Furthermore, 54 
pharmaceuticals designed for hospital use are suspected to have more adverse 55 
effects than other pharmaceuticals regarding their effect on the aquatic 56 
environment (Gómez-Canela et al., 2014). As such, in the last decade, much 57 
research has focused on understanding the occurrence and effects (Heberer, 58 
2002) of these contaminants in exposed organisms. Recently, we developed a 59 
multi-residue analytical method and determined occurrence of pharmaceuticals 60 
in tributaries of the River Thames and in Gammarus pulex (G. pulex) at ng L-1 61 
and ng g-1 concentrations respectively across eight sites (Miller et al., 2015). G. 62 
pulex is a small, low trophic level species of amphipod crustacean found in 63 
freshwaters across Europe and is very common throughout the United Kingdom 64 
(UK). G. pulex has many attributes for use in biomonitoring studies such 65 
including its important role in freshwater food chains where they serve as a food 66 
source for other invertebrates, fish and birds (Maltby et al., 2002). This 67 
organism has also been extensively used in contaminant monitoring including 68 
toxicity assays for various pollutants such as metals, pharmaceuticals, 69 
PAHs/PCBs and natural stressors which has shown the importance of this 70 
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species in environmental risk assessment (Bourgeault et al., 2013; Coulaud et 71 
al., 2011; De Lange et al., 2009; De Lange et al., 2006; Lebrun et al., 2012; 72 
Maltby et al., 2002;Pellet et al., 2014; Schaller et al., 2011; Vellinger et al., 73 
2012).  74 
 Studies of the effects of pharmaceuticals on low trophic level invertebrate 75 
organisms such as G. pulex using high resolution confirmatory chemical 76 
analysis techniques are lacking. In particular, metabolomics may reduce this 77 
knowledge gap by directing effect-based studies that reveal alternative markers 78 
or end-points to assess potential toxicity of contaminants. Advances in mass 79 
spectrometry (MS) over the last decade have enabled better characterization of 80 
the links between the metabolome and phenotype (Dettmer et al., 2007; Villas-81 
Bôas et al., 2005). Targeted liquid chromatography coupled to mass 82 
spectrometry (LC-MS) is the technique of choice for the reliable quantitation of 83 
known, pre-selected metabolites. It is an approach that will increasingly be used 84 
to apply knowledge discovered by non-targeted metabolomics; i.e. the eventual 85 
targeted measurement of a metabolic biomarker signature that can predict 86 
exposure to a specific environmental stress (Viant, 2008; Viant et al., 2013). 87 
Metabolomics studies have made use of high resolution, confirmatory analytical 88 
techniques such as nuclear magnetic resonance (NMR) or hyphenated MS 89 
technologies to characterise large numbers of compounds for metabolic 90 
profiling (targeted) (Zhang et al., 2012). With the development of high resolution 91 
mass spectrometry (HRMS), non-targeted screening of several thousand 92 
compounds has become possible for studying larger portions of the 93 
metabolome in contrast to NMR, which is often limited by low sensitivity (Dunn 94 
et al., 2005; Zhang et al., 2012). Early investigations focused on human, plant 95 
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and microbial metabolomes (Frisvad and Filtenborg, 1983; Horning and Horning 96 
1971; Taylor et al., 2002; Tweeddale et al., 1998). Other studies have identified 97 
changes in metabolomic profiles in mussels resulting from hypoxic conditions; 98 
biomarkers associated with withering syndrome in abalone sea snails; and 99 
responses to ethinylestradiol (EE2) by rainbow trout (Hines et al., 2007; 100 
Samuelsson et al., 2006; Viant et al., 2003). Approaches to characterize the 101 
metabolome can involve non-targeted or targeted strategies where for 102 
quantitative purposes, targeted analysis offers greater accuracy and precision 103 
(Griffiths et al., 2010; Lei et al., 2011).  104 
 The aim of the present study was to develop a targeted multi-residue 105 
method for the determination of 29 metabolites pertaining to different 106 
biochemical classes (amino acids, organic acids, nucleosides, nucleotides, and 107 
sugars) using LC-HRMS. As a full scan method also suitable for non-target 108 
analysis, the analytical performance of the method was evaluated quantitatively 109 
in terms of comprehensive mass spectral characterization, selectivity, 110 
sensitivity, intra- and inter-day precision, range and linearity. Acute toxicity of 26 111 
pharmaceuticals in G. pulex was also assessed as an initial screen for 112 
compound selection for metabolomics. Three pharmaceuticals showing low, 113 
median and high measured LC50 values were then selected for exposures at no-114 
observed-adverse-effect-level (NOAEL) and lowest-observed-adverse-effect-115 
level (LOAEL) concentrations to evaluate alterations in the metabolite profile at 116 
2, 6 and 24 h. This represents the first environmental metabolomics-based 117 
investigation of G. pulex by determining changes in endogenous metabolites in 118 
response to pharmaceutical residue exposure.  119 
2. Materials and Methods 120 
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2.1. Reagents, chemicals and consumables 121 
 All pharmaceuticals were purchased from Sigma-Aldrich (Steinheim, 122 
Germany) and Fluka (Buchs, Switzerland) with a purity of ≥97%. HPLC grade 123 
acetone, dimethylsulfoxide (DMSO), ethanol (EtOH) and methanol (MeOH) 124 
were purchased from Fischer Scientific (Loughborough, UK). Ultra-pure water 125 
was sourced from a Millipore Milli-Q water purification system with a specific 126 
resistance of 18.2 MΩ cm or greater (Millipore, Bedford, MA, USA). Stock 127 
solutions (40 mg mL-1) were prepared in ultrapure water, acetone, MeOH, EtOH 128 
or DMSO, respectively. All stock solutions were stored in silanised amber vials 129 
(40 mL) and at -20 ºC in the dark for optimum stability. Organic solvent 130 
concentration (acetone, MeOH, EtOH and DMSO) in aqueous solutions used 131 
for toxicity testing was negligible. Metabolite standards (organic acids, 132 
nucleosides, nucleotides, sugars and amino acids) were supplied by Sigma 133 
Aldrich (Steinheim, Germany) and Fluka (Buchs, Switzerland). In addition, the 134 
isotopically-labelled algal amino acid mixture (98 atom % as 13C, 98 atom % as 135 
15N) was provided from Sigma Aldrich. The targeted metabolome studied was 136 
comprised of 15 amino acids (AAs), 4 nucleosides, 2 nucleotides, 1 sugar, 3 137 
organic acids and 4 compounds related to other families. Full details of the 138 
target metabolites and the labelled compounds are shown in Table 1.  Finally, 139 
the 26 pharmaceutical compounds belonging to 12 different therapeutic classes 140 
are listed in Table S1. 141 
 142 
2.2. Sample collection and preparation 143 
 Adult G. pulex were collected several times between September 2014 and 144 
April 2015 from the River Cray, UK, a tributary of the River Darent that feeds 145 
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into the River Thames (51°23'10.5"N 0°06'34.8"E). Adult specimens were 146 
collected via the kick sampling netting method. Samples were transported back 147 
to the laboratory in NalgeneTM flasks containing a 500 mL grab sample of 148 
freshwater obtained from the River Cray. This site has previously been 149 
demonstrated to have low pharmaceutical contamination (<LOQ) (Miller et al., 150 
2015). After collection, G. pulex were stored in different artificial freshwater 151 
tanks and acclimatized for a minimum of 2-3 days at 15±2 ºC under a 12h:12h 152 
light:dark cycle to allow depuration of any residual contamination. The 153 
freshwater crustaceans were fed ad libitum with a minimum of three horse-154 
chestnut leaf discs (Ashauer et al., 2011). Artificial freshwater (AFW) was 155 
prepared following United States Environmental Protection Agency (USEPA) 156 
regulation (USEPA 2002). Briefly, 1.20 g MgSO4, 1.92 g NaHCO3 and 0.080 g 157 
KCl were added to 19 L of ultra-pure water that was aerated overnight. In 158 
parallel, 1.20 g of CaSO4·2H2O was added to 1 L of Milli-Q water and mixed 159 
with the previous salt solution to make a total 20 L of AFW  (USEPA 2002). 160 
 161 
2.3. Pharmaceutical exposures 162 
 To select specific pharmaceuticals, the concentrations for exposures and 163 
subsequent metabolite profiling, a series of acute toxicity tests to 26 164 
pharmaceuticals were initially performed following the Organization for 165 
Economic Co-operation and Development (OECD) 1488/94 guideline 166 
(European Communities Commission 1996). Lethal median concentration 167 
effects and its 95% confidence interval (CI), were estimated by fitting immobility 168 
concentration responses to the Hill regression model (Eq. 1). 169 
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      Eq. 1 170 
 171 
 172 
Where, I(Ci) is the proportion of immobile animals at concentration Ci; Ci is the 173 
concentration of the respective compound (i); LC50 is the median lethal 174 
concentration to the 50% of population and Hill is the shape constant, which 175 
depends on the parameters adjusted in the regression model. From these 176 
toxicity profiles the NOAEL and the LOAEL were determined. Exposure 177 
experiments were performed in Pyrex® beakers, each containing 200 mL of 178 
AFW at 15oC and ten adult animals (>5 mg wet weight, ww). Live/dead animals 179 
were counted after 24 h by gently prodding and observing movement of 180 
appendages. The pharmaceutical concentrations tested were in the range of 181 
0.01 to 250 mg L-1. Control (AFW only) and solvent controls showed no 182 
measurable toxicity. Concentrations where 100, 50 and 0 % of the animals died 183 
were repeated in duplicate or triplicate. 184 
 From the initial toxicity tests on 26 pharmaceuticals, 3  were chosen for 185 
metabolomics studies representing the high (triclosan), medium (nimesulide) 186 
and low (propranolol) range of measured acute toxicity. Each exposure 187 
consisted of G. pulex exposed at the NOAEL (C1) and a second higher 188 
concentration at the LOAEL (C2) as follows: triclosan, C1 = 0.1 mg L
-1/C2 = 0.3 189 
mg L-1; nimesulide, C1 = 0.5 mg L
-1/C2 =1.4 mg L
-1; and propranolol, C1 = 100 190 
mg L-1/C2 = 153 mg L
-1. Approximately 100 specimens were introduced in a 191 
tank containing 1 L of AFW (control), 1 L of AFW spiked with C1 and 1 L of AFW 192 






















pool of 6-7 animals for each replicate) were collected, frozen on dry ice and 194 
then stored at -80 ºC before metabolite profiling was performed. A preliminary 195 
extraction protocol with 1, 3, 6 and 10 animals showed that a pool of 6-7 G. 196 
pulex provided the best method recoveries.  197 
 Quantification of pharmaceutical concentrations in G. pulex at the 24 h 198 
exposure interval was performed. Separate exposures were set up in triplicate 199 
in beakers containing 200 mL of exposure solution (AFW spiked with the 200 
respective C1 pharmaceutical dose) and 20 organisms. At 24 h, animals were 201 
immediately rinsed with ultra-pure water and then frozen at -20 oC for 24 hours. 202 
Full analytical method details are described in Miller et al., 2015. Prior to 203 
extraction, frozen G. pulex samples were lyophilised at -50 ºC under vacuum for 204 
48 hours and milled in an agate mortar to a fine powder. For each analysis, 20 205 
mg of a lyophilised composite sample were transferred to 2 mL polypropylene 206 
tubes (Eppendorf®, Hamburg, Germany), for solid-liquid extraction (SLE). After 207 
the addition of 80 µL of stable isotope-labelled internal standards at 208 
concentrations between 3.29 and 43.11 ng µL-1 (final concentration dependent 209 
on the AA concentration in the stock reference material mixture), 800 µL of 210 
MeOH:HPLC water (90:10) mixture was added and the samples were 211 
thoroughly mixed using a Vortex mixer. Then, samples were shaken for 25 min 212 
on a vibration plate (IKA® KS 260 basic) and centrifuged at 14000 rpm for 25 213 
min at 0ºC. Finally, the supernatant was transferred to a chromatographic vial 214 
by using a 0.20 µM syringe filter (Whatman, GE Healthcare Life Sciences, 215 
Buckinghamshire, UK). All samples were stored at -80ºC until LC-HRMS 216 




2.4.  Internal pharmaceutical residue determination and metabolite profiling  219 
 Internal concentrations of pharmaceuticals in G. pulex were determined 220 
using a previously described method (Miller et al., 2015). Briefly, 50 mg of 221 
lyophilised G. pulex were extracted in 5 mL of acetonitrile and pre-concentrated 222 
on Oasis HLB SPE cartridges (6 mL, 200 mg sorbent). The extract was eluted, 223 
dried-down and reconstituted in starting LC mobile phase. The chromatographic 224 
separation followed a 75 min gradient (including 12.5 min re-equilibration) using 225 
water and acetonitrile with 10 mM ammonium acetate salt. Separation was 226 
achieved using a Waters Sunfire C18 reversed-phase column (2.1 x 150 mm, 227 
2.5 μM particle size) and detection was performed by a Waters Quattro triple 228 
quadrupole mass analyser using positive and negative electrospray ionisation 229 
polarity switching (Waters Corporation, Milford, MA, USA). Organic acids, 230 
nucleosides, nucleotides, sugars and AAs were measured using LC–HRMS. An 231 
ExactiveTM mass spectrometer equipped with heated electrospray ionization (H-232 
ESI) source was used (Thermo Fisher Scientific, Bremen, Germany). The 233 
system was equipped with a HTC PAL autosampler and a Surveyor MS Plus 234 
pump. A TSK Gel-Amide 80 column (2 x 250 mm, 5 µm) for analyte separation 235 
was purchased from Sigma Aldrich. Mobile phases were binary mixtures of 236 
acetonitrile (A) and 5 mM ammonium acetate (pH 5) in HPLC-grade water (B). 237 
Gradient elution started at 75% A and 25% B, which was increased linearly to 238 
30% B in 8 min, increased linearly to 60% B to 12 min and then held for a 239 
further 5 min. Initial conditions were returned in 3 min and the system was 240 
stabilized after a total equilibration time of 10 min (total run time = 30 min). The 241 
flow rate was set at 150 µL min−1 and the injection volume was 5 µL. 242 
Metabolites were analysed under positive/negative ESI mode, but better 243 
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resolution was obtained in negative ionization mode and so this was used for all 244 
experiments. Full scan acquisition over a mass range of 80–800 Da was 245 
performed at 70,000 full width at half maximum (FWHM) and spray voltage at 246 
3.00 kV, capillary voltage at 30 V, skimmer voltage at 28 V and tube lens 247 
voltage at 130 V were used. A sheath gas flow rate of 45 arbitrary units (au), an 248 
auxiliary gas flow rate of 10 au and a capillary temperature at 300 ºC were 249 
selected. 250 
 251 
2.5.  Method performance and quantification 252 
 Method performance for internal pharmaceutical residue concentrations in 253 
G. pulex are described elsewhere (Miller et al., 2015). Here, pharmaceutical 254 
residue quantification in exposed G. pulex was performed by a 3-point matrix-255 
matched calibration curve. For nimesulide, spiking concentrations were 2.5, 5 256 
and 10 μg g-1; for triclosan, these were 1, 2.5 and 5 μg g-1; and for propranolol 257 
these were 1, 2.5 and 5 mg g-1. The calibration range for endogenous 258 
metabolites was from 0.01 to 15 ng μL−1, using 9 calibration points. The algal 259 
amino acid mixture-13C,15N (see Table 1) was used as internal standard (IS) for 260 
extraction and analytical control. L-ornithine hydrochloride, inosine, thymidine, 261 
taurine, 1,7-dimethylxanthine and (-)-riboflavin were quantified using either 262 
13C,15N-proline or 13C,15N-tyrosine as the internal standard. The remaining 15 263 
compounds were quantified using external calibration and the target compound 264 
itself was used as external standard. The instrumental detection limit (IDL) was 265 
initially calculated as that concentration giving a signal intensity of 1×103, and 266 
afterwards measured experimentally by injecting a standard concentration that 267 
gave this signal intensity. The method detection limit (MDL) was calculated 268 
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following the same procedure, using spiked lyophilised G. pulex samples at a 269 
concentration of 1 µg g−1. Intra-assay variation was assessed using five 270 
consecutive injections of 5 ng μL−1 standard solution, and inter-assay variation 271 
was determined by measuring the same standard solution on four different 272 
days. Solvent blanks did not contain any of the investigated analytes, indicating 273 
no carry-over between LC-HRMS runs. Recovery studies were performed in 274 
triplicate, using lyophilised G. pulex samples spiked at 1 μg g−1 with the 275 
metabolites mixture and the algal amino acid mixture-13C, 15N. Five replicates of 276 
a pool with 6-7 G. pulex were analyzed first and the traces of target compounds 277 
were subtracted.  278 
 279 
2.6. Statistical analysis 280 
 Two-way ANOVA considering significant p values ≤0.05 was used as a first 281 
step to select metabolites with significant changes and to further explore their 282 
concentration and time trends. Thus, p values were derived and examined to 283 
determine any differences between exposed and control specimens, and to 284 
evaluate the effect of the exposure time. All data satisfied the assumptions of 285 
normality and homoscedasticity. In addition, all calculations were performed in 286 
MATLAB software version R2013b. 287 
3. Results and discussion 288 
3.1. Analytical method performance 289 
 Good correlation coefficients (R2≥0.99) were obtained for 29 metabolites 290 
(Table 1). Responses for fifteen metabolites were linear from 0.05 to 15 ng μL−1; 291 
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and for 11 other metabolites, linearity ranged from 0.1 to 15 ng μL−1.  Signals for 292 
inosine and hypoxanthine were linear over the range of 0.01 to 15 ng μL−1; and 293 
ADP in the range 3 to 15 ng μL−1. Therefore, given that this represents a lower 294 
concentration range of 10 to 1500 ng g-1, these were considered fit for purpose 295 
for this study. IDL ranged from 0.002 to 0.20 ng, and intra and inter-day 296 
precision ranges were from 1 to 14% and from 0.1 to 19%, respectively at the 5 297 
ng µL−1 concentration level. Twenty seven compounds showed recoveries 298 
within the range of 42±8% to 138±2% (Table 1). Overall, recoveries were 299 
acceptable and showed excellent precision. However, the two nucleotides ADP 300 
and NADH displayed poorer recoveries of 25±11% and 162±10%, respectively. 301 
Finally, the MDL ranged from 0.04 (inosine) to 37.3 ng g−1 (creatine), with the 302 
exception of ADP, for which sensitivity was low as would be expected due to the 303 
lower recovery observed (MDL: 162 ng g−1). The extracted ion chromatograms 304 
of a target metabolite mixed solution at 5 ng µL−1 using the TSK Gel-Amide 80 305 
HILIC column is shown in Figure 1. In summary, the method performance of this 306 
analytical method indicated that reliable quantitative measurements could be 307 
made for most metabolites and with minimal variance contribution from the 308 
matrix. Moreover, as this method incorporated HRMS in full-scan mode, post 309 
hoc untargeted data analysis of the metabolome remains possible if required. 310 
 311 
3.2. Acute toxicity, 24-hour pharmaceutical exposures and observed changes in 312 
target metabolite concentrations  313 
Acute toxicity tests revealed LC50 at the mg L
-1 level for most of the 26 tested 314 
pharmaceuticals. Similar values have been obtained in other freshwater 315 
crustaceans (see Table S3). Kim et al. (2009) studied the acute toxicity of 316 
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pharmaceuticals and personal care products in the freshwater crustacean, 317 
Thamnocephalus platyurus (T. platyurus). They reported a similar LC50 value to 318 
the present study for triclosan (0.57 mg L-1), but not for propranolol which lay at 319 
10.31 mg L-1 (Kim et al., 2009). These values provide a means of ranking the 320 
toxic risk, but such values are not environmentally relevant as pharmaceuticals 321 
are generally found at concentrations approximately one to two orders of 322 
magnitude less (Miller et al. 2015). Therefore, it is unlikely that the majority of 323 
these compounds will display any significant acute toxicity. Nonetheless, as a 324 
starting point and based on these data, exposures were performed at NOAEL 325 
and LOAEL concentrations for triclosan, nimesulide and propranolol to 326 
represent compounds at the high, median and low range of measured LC50 327 
(Figures S1-S3).  328 
 329 
3.2.1 Triclosan  330 
 Triclosan, the most toxic of the selected pharmaceuticals (LC50 0.57 mg 331 
L-1) measured here, caused changes in the metabolite concentrations in G. 332 
pulex at 0.1 mg L-1 (C1) and 0.3 mg L
-1 (C2), and was dose responsive. 333 
Exposure to triclosan produced significant changes (Two-way ANOVA, p<0.05) 334 
in 19 metabolites: 13 amino acids (L-alanine, cytidine, L-citrulline, L-isoleucine, 335 
L-leucine, L-methionine, L-phenylalanine, L-proline, taurine, L-threonine, L-336 
tryptophan, L-tyrosine and L-valine), inosine and uridine (nucleosides) and 337 
others like trehalose, hypoxanthine, riboflavin and thymidine (Table 2 and 338 
Figure S4). However, only the concentration of 37% of metabolites changed 339 
significantly (up or down) across the exposure time. L-isoleucine, L-340 
phenylalanine, L-(-)-proline, taurine, L-threonine, L-tyrosine, L-valine, inosine 341 
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and thymidine concentrations varied significantly (p<0.05) with exposure 342 
duration (Table 2). A 2-way ANOVA was used to evaluate the interaction 343 
between dose and time factors. Cytidine, L-methionine, L-phenylalanine and L-344 
(-)-proline were the only metabolites that had significant interactions (Table 2). 345 
As shown in Figure S4, all metabolites except L-citrulline changed in their mean 346 
concentrations at C1 relative to the controls. Some metabolites increased more 347 
than two to three-fold in comparison to controls such as L-tryptophan, 348 
hypoxanthine, L-alanine, L-isoleucine, L-threonine, L-valine and L-thymidine. In 349 
other cases, measured concentrations between the exposed and control 350 
samples decreased over time (ADP and L-proline). Similar trends occurred at 351 
C2 where the 75% of the metabolites increased in their concentration, with the 352 
remaining metabolites showing no significant changes (also see Table S1). 353 
Table S2 shows the metabolite concentrations determined from all conditions 354 
studied. To more conveniently highlight trends, Figure 2 represents the fold 355 
change values at each exposure concentration with respect to controls and 356 
plotted in a heat map and hierarchical analysis revealed two distinct clusters (A 357 
& B). In general, and for each metabolite in Cluster A of Figure 2, the fold 358 
changes in gammarid metabolites exposed at C1 decreased across the 24-h 359 
period. On the contrary, Cluster B generally showed the opposite trend where 360 
concentrations of metabolites mostly increased. In the case of samples exposed 361 
at C2, eight metabolites of Cluster A (L-aspartic acid, L-leucine, L-valine, L-362 
methionine, inosine, taurine, L-tyrosine and thymidine) had a fold increase and 363 
the remainder showed a slight decrease in concentration. The metabolites of 364 
Cluster B also showed fold decreases along the 24-h period and the opposite 365 




3.2.2 Nimesulide  368 
 Exposure to nimesulide produced significant changes (Two-way ANOVA, 369 
P<0.05) for 83% of the metabolites analysed, including most amino acids 370 
(except L-alanine), such as inosine, uridine and other metabolites including 371 
hypoxanthine, riboflavin and thymidine (Table 2 and Figure S5). L-2-amino-n-372 
butyric (AABA), L-alanine, L-aspartic acid, cytidine, L-citrulline, L-leucine, L-(-)-373 
proline, L-serine, trehalose and thymidine showed a time-related effect (Table 374 
2), affecting 42% of the metabolites studied. On the other hand, considering the 375 
interaction between time and dose factor, significant differences (p<0.05) in all 376 
metabolites except for L-tyrosine and NADH were detected (Table 2). 377 
Nimesulide exposures induced changes in the metabolome of G. pulex in 378 
comparison to controls (Figure S5). A heat map of nimesulide was prepared  as 379 
before and hierarchical analysis again revealed two clusters (Figure 3). In this 380 
case, at C1, all the metabolites except trehalose had fold increases along the 381 
24-h period (Cluster A, Figure 3). Specifically, L-alanine, (-)-riboflavin, cytidine, 382 
hypoxanthine, L-tryptophan, inosine, taurine, L-tyrosine and NADH suffered the 383 
more important changes (garnet colour). On the other hand, trehalose (Cluster 384 
B, Figure 3) showed the opposite trend and, at 24-h exposure time, the fold 385 
change had decreased (blue). In the samples exposed at C2, the metabolites in 386 
Cluster A began with positive fold changes (red/orange) at 2-h exposure time 387 
and decreased (blue) at 24-h exposure time, with the exception of NADH, ADP 388 
and trehalose (Cluster B, Figure 3).   389 
3.2.3 Propranolol  390 
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 Exposure to propranolol produced significant changes (based on two-391 
way ANOVA, p <0.05 analysis) in 8 out of 15 AAs (AABA, cytidine, L-392 
methionine, L-proline, L-serine, taurine, L-tryptophan and L-valine), uridine 393 
(nucleoside), ADP (nucleotide) and others like hypoxanthine, riboflavin and 394 
thymidine (Table 2 and Figure S6). Moreover, the exposure time affected 71% 395 
of the metabolites studied. L-Alanine, L-aspartic acid, cytidine, L-isoleucine, L-396 
leucine, L-methionine, L-phenylalanine, L-(-)-proline, L-threonine, L-tryptophan, 397 
L-tyrosine, L-valine, inosine, uridine, trehalose, hypoxanthine and thymidine 398 
displayed significant changes (p values < 0.05) across the 24 h experiments, 399 
see Table 2. Exposures at C1, a concentration below LC10, showed significant 400 
changes in the concentrations of the metabolites with respect to controls. For 401 
example, AABA increased its concentration by more than two-fold (Figure S6). 402 
In other metabolites, decreasing metabolite concentrations were observed such 403 
as taurine, an essential amino acid for cardiovascular function and the central 404 
nervous system, or inosine, a nucleoside formed when hypoxanthine is 405 
attached to a ribose ring. Table S2 shows the concentrations of the metabolites 406 
determined from all exposures. At the higher exposure concentration, 153 mg  407 
L-1 (C2), similar metabolite concentration changes occurred for AABA, taurine 408 
and inosine. Additionally, hypoxanthine and thymidine concentrations were 409 
different compared to controls (Figure S6). In the samples exposed at C1, all the 410 
metabolites in Cluster A (Figure 4) had fold decreases along the 24-h exposure 411 
time. However, L-citrulline and L-tyrosine (Cluster B, Figure 4) and ADP had 412 
fold increases at 24-h. Finally, in the samples at C2, the general trend in Cluster 413 
A plus ADP is that the metabolites had fold increases along 24-h, with the 414 
exception of NADH and taurine. Moreover, the metabolites in Cluster B of the 415 
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Figure 4 (L-citrulline and L-tyrosine) also decreased their fold changes at 24-h 416 
exposure time.  417 
 418 
3.3  Metabolic pathways potentially affected by selected single pharmaceutical 419 
exposures 420 
 Little or no reported metabolomics or pathway-based analysis data exists 421 
for G. pulex in the literature to our knowledge. However, changes in its 422 
metabolic profile following exposure to pharmaceuticals may result in processes 423 
that are suggestive of either metabolic (i.e detoxification) or toxic responses. 424 
Firstly, and to support this, the internal concentrations were determined for the 425 
two compounds nimesulide and propranolol at the C1 concentration at 24-h time 426 
interval. Triclosan was detected, but was unfortunately not quantifiable due to 427 
poor standard addition linearity (and similarly poor method performance as a 428 
whole). The C1 propranolol dose resulted in measured concentrations up to 429 
4.9±0.3 mg g-1 (dry weight) and nimesulide reached a mean concentration of 430 
12.2±4.1 μg g-1 which are both significantly higher concentrations than the 431 
estimated dose required for therapeutic effects in humans. When comparing to 432 
environmental occurrence concentrations, these compounds did not exceed 36 433 
ng g-1 in G. pulex (Miller et al., 2015) and other studies in aquatic invertebrates 434 
often report concentrations of less than 200 ng g-1 (Dodder et al., 2014; Huerta 435 
et al., 2015). However, and although the concentrations determined here are 436 
unlikely to be seen in the environment, measurement using such analytical 437 
methods enables interpretation of metabolic responses and potentially 438 
metabolic pathways indicative of adverse effects in the future for risk 439 




The different responses may be elicited through numerous complex biochemical 442 
pathways such as nucleic acid expression, protein synthesis, enzymatic 443 
processes and signalling cascades. Thus, identifying and quantifying metabolite 444 
change is a useful starting point perhaps to direct metabolomics and extended 445 
pathway-based research in the future. The advantage of operating HRMS mass 446 
analysers in full-scan mode (as in the present study) is that such further 447 
qualitative meta-analysis of the data is still possible using untargeted and/or 448 
chemometric approaches at a later time (Farrés et al., 2014). The unbiased 449 
nature of non-target metabolomics would also allow the interpretation of 450 
metabolic responses in relation to known mode-of-action pathways for 451 
pharmaceuticals. Nonetheless, this was beyond the scope of this work and 452 
future work will be pursued in this direction. A general observation was that 453 
control levels of metabolites showed relatively large scatter in specific cases. 454 
During the study the organisms were collected from the same site and were of 455 
similar size, but the variances in metabolite profiles of the controls are likely to 456 
have resulted from differences between individuals such as their age, moult 457 
cycle stage and gender. Furthermore, acclimatisation of mussel populations in 458 
laboratory conditions has also been demonstrated to lead to increased 459 
metabolic variability (Hines et al., 2007).  460 
3.3.1. Protein synthesis  461 
 Exposure to all three pharmaceuticals resulted in an increase in thymidine 462 
and inosine concentrations when compared to controls. Amongst other potential 463 
reasons, their increase in concentration could be related to increases in protein 464 
synthesis as they are associated with tRNA. Cytidine concentrations varied 465 
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between exposure concentrations and time points for all compounds. Triclosan 466 
had elevated cytidine concentrations at both 2 and 6-h time intervals relative to 467 
controls in the C1 exposure. The same effect was not observed in C2, often 468 
remaining close to the control levels except at the 6-h time interval. Cytidine in 469 
the nimesulide exposure was upregulated relative to controls at C1, whereas C2 470 
showed a steady increase in cytidine concentrations over the 24-h exposure 471 
period. For propranolol, cytidine concentrations remained below controls at C2 472 
and were initially upregulated at C1 before decreasing below control levels at 24 473 
h. Uridine showed no obvious differences between controls for either exposure 474 
concentration in propranolol. Uridine was upregulated in the nimesulide C2 475 
exposure by 24-h whereas in the C1 remained higher than controls at all time 476 
points. Triclosan showed increased uridine concentrations in both exposures at 477 
the 2 and 6-h intervals when compared with control levels, the C2 uridine 478 
concentrations returned to the control level at 24-h. As uridine is absent from 479 
DNA and only present in RNA, it is plausible that together these four 480 
nucleosides are generally indicative of upregulation of protein synthesis which is 481 
potentially induced by all three pharmaceuticals. The upregulation could be 482 
considered as a general metabolic response to such xenobiotic exposure, for 483 
example, via the production of P450 enzymes (Marionnet et al., 1997; Ortiz-484 
Delgado et al., 2008). Triclosan has also been shown to increase the P450 485 
content of rat liver microsomes (Kanetoshi et al., 1992; Liang et al., 2013). 486 
3.3.2. Xenometabolic pathways 487 
 The internal concentrations reached in G. pulex exceed the human 488 
therapeutic doses and thus are likely to induce xenometabolism by means of 489 
enzymes associated with phase I and II metabolism. It is possible that the 490 
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increased content of uridine is also related to phase II metabolic processes. 491 
Uridine, when converted to a triphosphate nucleotide (UTP), is involved in the 492 
biosynthesis of uridine diphosphate glucose (UDPG) which serves as a 493 
precursor of uridine glucuronic acid, the primary substrate for phase II 494 
glucuronidation reactions catalysed by uridine 5’-diphospho-495 
glucuronosyltransferase (UGT). Major metabolites associated with these three 496 
pharmaceuticals are glucuronide conjugates, which support this argument 497 
(Macpherson et al., 2013; Walle et al., 1985; Wu et al., 2010). Riboflavin also 498 
showed statistically significant 2-3 fold increases in concentration relative to 499 
control concentrations. This metabolite is essential for xenometabolic processes 500 
as it forms part of flavin adenine nucleotide (FAD) and flavin mononucleotide 501 
(FMN), which are essential cofactors for redox reactions involving P450 502 
enzymes and flavin-containing monooxygenases (FMOs). These cofactors are 503 
also required for regeneration of reduced glutathione (GSH) from its oxidized 504 
form glutathione disulfide (GSSG).  505 
 At C1 and C2 nimesulide exposures, AABA showed a significant reduction in 506 
concentration and also decreased over the course of the experiment. This 507 
metabolite is a precursor to ophthalmic acid, which is associated with oxidative 508 
stress and the induction of ophthalmic acid pathways is shown when glutathione 509 
levels are reduced (Soga et al., 2006). As nimesulide has been shown to 510 
reduce GSH levels as well as induce oxidative stress, it is suggestive that the 511 
low levels of AABA are a result of its conversion to ophthalmic acid, but this 512 
requires confirmation (Chatterjee et al., 2006; Mingatto et al., 2002; Singh et al., 513 
2010). It has been suggested that the physiological significance in the 514 
production of AABA is that it is a cofactor in the transport of glucuronide 515 
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metabolites in the multi-drug resistance protein 1 (MRP-1) and thus required for 516 
elimination of xenobiotics (Soga et al., 2006). Lastly, perturbations in 517 
methionine concentrations may also be indicative of xenometabolic pathways. 518 
The concentrations of methionine in all exposures were elevated relative to 519 
control with the exception of the 2 h C2 sampling point in the propranolol 520 
exposure. Methionine acts as a precursor to S-adenosyl methionine (SAM) that 521 
is involved in methylation reactions for xenobiotic metabolism. Triclosan, for 522 
example, undergoes methylation during metabolism to methyltriclosan and 523 
therefore may explain its elevated concentrations in both triclosan exposures 524 
(Wu et al., 2010). Finally, this compound also serves as a precursor to GSH 525 
biosynthesis and therefore may be elevated even when xenobiotics are not 526 
methylated during detoxification.   527 
3.3.3. Signaling cascade 528 
 Tryptophan was significantly expressed at increased concentrations in all 529 
three pharmaceutical exposures at both C1 and C2. This AA acts as a precursor 530 
to serotonin that is often released as a stress response. It is possible that the 531 
exposure to these pharmaceuticals induced a stress response. Indeed, C2 is set 532 
at the LOAEL with mortality as the adverse effect, which upregulated the 533 
synthesis of tryptophan for which serotonin synthesis is dependent (Joseph and 534 
Kennett 1983). Xenobiotics have been previously shown to induce the release 535 
of serotonin in rats (Yokogoshi 1989). However, it is also possible that 536 
tryptophan is produced in response to reactive oxygen and nitrogen species 537 
(ROS/RNS) produced by the metabolism of the pharmaceuticals (Peyrot and 538 
Ducrocq 2008). Triclosan displayed the highest concentrations of tryptophan 539 
reaching up to 142 µg g-1 when exposed at C2. The higher toxicity of this 540 
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compound may lead to added stress in comparison to propranolol and 541 
nimesulide. The amino acid proline also showed statistically significant changes 542 
during the three exposures. In particular, the C1 exposures showed a decrease 543 
in proline over time until they approximately reached control levels at the 24-h 544 
time interval. The same trend is not observed in the C2 exposures and is more 545 
variable when compared to the controls. Proline has been shown in previous 546 
studies to be important during stress responses as this amino acid has roles in 547 
preventing oxidative stress, maintenance of osmoregulation, energy production, 548 
and many other biological functions in plants and amphipods (Maity, S. et al., 549 
2012; Choudhary, M. et al., 2007). .  550 
 551 
4 Conclusions 552 
 A comprehensive optimisation of a targeted multi-residue method for the 553 
quantitative determination of 29 metabolites from different biochemical classes 554 
using LC-HRMS was performed. The acute toxicity (LC50) was also estimated 555 
for 26 pharmaceuticals and revealed that triclosan was the most toxic 556 
compound to G. pulex. However, the reliance on acute toxicity data such as 557 
LC50 for pharmaceutical risk assessment may ultimately not be realistic as these 558 
were at least one-two orders of magnitudes higher than concentrations typically 559 
found in the aquatic environment. Exposures performed at the NOAEL and 560 
LOAEL with three pharmaceuticals across the range of measured toxicity 561 
resulted in quantifiable changes in the metabolome in G. pulex. Measured 562 
internal concentrations of nimesulide and propranolol were far higher than the 563 
daily recommended doses for therapeutic effects in humans. Alterations in 564 
metabolite concentrations were observed, which could be involved in several 565 
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different pathways relating to protein synthesis, oxidative stress and signalling 566 
cascades. However, further efforts are required to fully characterise and 567 
understand the effects these contaminants have on any specific pathway. In 568 
Greater knowledge using such analytical methods for quantitative 569 
determinations of endogenous metabolites in aquatic organisms can now be 570 
acquired. In addition, the use of full-scan HRMS detection enables non-target 571 
meta-analysis to be performed in the future using chemometric tools that could 572 
identify biomarkers of exposure and effect for use in the environmental risk 573 
assessment of pharmaceuticals.   574 
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Table 1. Target analytes for metabolic profiling. Kegg number, molecular formula, molecular weight (Mw) and mass spectral characterization (ordered by 
metabolic group) by LC-HRMS. Instrumental method performance. F: slope; R
2
: regression coefficient; IDL: instrumental detection limit; RSD: relative standard 









































C00334 C4H9NO2 103.06 103.0633 102.0560 0.05-15 External 1e6 0.993 0.06 9 2 107±14 13.9 
L-Alanine C00041 C3H7NO2 89.05 89.0477 88.0404 0.05-15 External 1e6 0.998 0.03 8 8 92±9 0.99 
L-Aspartic acid C00049 C4H7NO4 133.04 133.0375 132.0302 0.05-15 External 4e5 0.995 0.20 4 14 87±11 22.7 
L-Citrulline C00327 C6H13N3O3 175.09 175.0957 174.0884 0.1-15 External 1e6 0.999 0.15 2 6 87±1 23.9 
L-Isoleucine C00407 C6H13NO2 131.09 131.0946 130.0873 0.1-15 Internal 4.5 0.998 0.03 12 6 42±8 0.28 
L-Leucine C00123 C6H13NO2 131.09 131.0946 130.0873 0.1-15 Internal 1.6 0.994 0.02 13 9 99±1 0.47 
L-Methionine C00073 C5H11NO2S 149.05 149.0510 148.0437 0.05-15 Internal 21 0.997 0.02 5 6 67±14 2.66 
L-Ornithine 
hydrochloride 
C00077 C5H12N2O2 132.10 132.0899 131.0826 0.05-15 Internal 0.83 0.994 0.01 4 8 109±6 3.51 
L-Phenylalanine C00079 C9H11NO2 165.08 165.0790 164.0717 0.1-15 Internal 1.6 0.996 0.02 14 14 97±4 0.42 
L-(-)-Proline C00148 C5H9NO2 115.06 115.0633 114.0560 0.05-15 Internal 1.2 0.997 0.01 5 11 87±8 1.13 
L-Serine C00065 C3H7NO3 105.04 105.0426 104.0353 0.05-15 Internal 1.1 0.996 0.01 13 13 88±14 9.50 
L-Threonine C00188 C4H9NO3 119.05 119.0582 118.0509 0.1-15 Internal 2.0 0.999 0.2 13 7 103±11 3.59 
L-Tryptophan C00078 C11H12N2O2 204.09 204.0899 203.0826 0.1-15 External 7e6 0.998 0.02 8 6 102±5 1.35 
L-Tyrosine C00082 C9H11NO3 181.07 181.0739 180.0666 0.1-15 External 2.1 0.996 0.03 7 12 80±8 0.35 
L-Valine C00183 C5H11NO2 117.08 117.0790 116.0717 0.05-15 Internal 1.3 0.991 0.05 12 13 91±6 0.80 
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* Internal standards used to quantify (Algal AA mixture).  
 
Cytidine C00475 C9H13N3O5 243.08 243.0855 242.0777 0.05-15 External 3e6 0.999 0.01 8 1 110±9 1.94 
Inosine C00294 C10H12N4O5 268.09 268.0808 267.0734 0.01-15 Internal 1.01 0.995 0.002 1 14 108±8 0.04 
Thymidine C00214 C10H14N2O5 242.20 242.0903 241.0829 0.05-15 Internal 0.7 0.991 0.01 7 5 99±7 0.50 
Uridine C00299 C9H12N2O6 244.07 244.0695 243.0622 0.05-15 External 2e6 0.997 0.03 7 5 138±2 0.33 
ADP C00008 C10H15N5O10P2 427.03 427.0294 426.0221 3-15 External 7e5 0.993 0.15 9 11 25±11 162 
NADH C00004 C21H27N7O14P2 663.07 663.1091 662.1018 0.1-15 External 1e6 0.990 0.06 2 19 162±10 7.80 
Trehalose C01083 C12H22O11 342.12 342.1162 341.1089 0.05-15 External 2e6 0.996 0.01 10 0.2 81±7 1.03 
Creatine C00300 C4H9N3O2 131.07 131.0695 130.0622 0.1-15 External 3e5 0.991 0.11 3 0.5 107±2 37.3 
Phthalic acid C01606 C8H6O4 166.14 166.0266 165.0193 0.1-15 External 1e6 0.997 0.01 6 7 102±2 13.6 
Taurine C00245 C2H7NO3S 125.01 125.0147 124.0073 0.05-15 Internal 2.03 0.992 0.03 8 14 92±20 0.23 
1,7-Dimethylxanthine C13747 C7H8N4O2 180.20 180.0647 179.0574 0.05-15 Internal 1.19 0.997 0.01 10 13 72±4 2.33 
Hypoxanthine C00262 C5H4N4O 136.04 136.0385 135.0312 0.01-15 External 8e6 0.991 0.004 4 9 102±7 0.47 
Pyridoxine C00314 C8H11NO3 169.20 169.0739 168.0666 0.05-15 External 3e6 0.94 0.07 6 0.1 105±10 21.6 


































N-Valine* - C5H11NO2 123.10 123.0925 122.0852 -  - - - - - - - - 
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Table 2. Two-way ANOVA indicating p values for changes in metabolite concentrations based 
on time and dose factor. In bold, significant changes where p < 0.05. 
 p-value 























AABA 0.49 0.23 0.91 - 3e-4 0.003 - 0.24 0.32 
L-Alanine - 0.19 0.15 0.53 - 6e-4 - 0.001 0.03 
L-aspartic acid 0.17 0.37 0.25 2e-4 0.005 0.004 0.28 0.04 0.44 
Cytidine 0.001 0.08 0.02 - 0.02 - 5e-6 1e-5 1e-6 
L-Citrulline 0.01 0.81 0.95 4e-6 2e-5 8e-6 0.53 0.29 0.07 
L-Isoleucine - 9e-4 0.12 - 0.29 - 0.06 3e-4 0.003 
L-Leucine 0.01 0.47 0.73 - 0.003 - 0.25 - - 
L-Methionine - 0.18 0.003 - 0.15 1e-4 0.003 0.005 0.007 
L-ornithine 
hydrochloride 
Not detected in Gammarus pulex organism 
L-Phenylalanine - 0.001 0.001 - 0.53 0.0001 0.69 - 0.001 
L-(-)-Proline - 0.001 0.01 4e-7 6e-13 8e-9 - - 2e-4 
L-Serine 0.21 0.05 0.23 0.04 0.02 0.03 - 0.73 0.01 
Taurine - 0.002 0.10 - 0.58 0.002 0.03 0.05 0.75 
L-Threonine - 0.03 0.07 - 0.07 0.001 0.34 - 0.001 
L-Tryptophan - 0.28 0.53 - 0.08 - 0.0012 - - 
L-Tyrosine - 0.01 0.40 0.003 0.97 0.12 0.70 0.01 0.27 
L-Valine - 0.01 0.05 - 0.42 - 5e-4 2e-4 - 
Inosine - 0.01 0.11 - 0.17 0.03 0.12 0.002 0.27 
Uridine 8e-4 0.45 0.26 - 0.98 - 0.002 6e-4 0.009 
ADP 0.21 0.25 0.74 0.04 0.14 0.01 0.02 0.87 0.64 
NADH 0.05 0.41 0.31 0.49 0.72 0.12 0.52 0.58 0.83 
Trehalose 0.03 0.11 0.08 0.07 - - 0.21 - - 
Creatine Not detected in Gammarus pulex organism 
1,7-dimethylxanthine Not detected in Gammarus pulex organism 
Hypoxanthine - 0.08 0.07 - 0.14 - 1e-6 4e-5 8e-7 
Phtalic acid Not detected in Gammarus pulex organism 
Pyridoxine (vitamin 
B6) 
Not detected in Gammarus pulex organism 
(-)-Riboflavin 0.01 0.49 0.36 - 0.46 0.002 3e-4 0.69 0.008 
Thymidine - 0.01 0.12 - 7e-4 - 4e-4 0.009 2e-4 
*Dose factor corresponds at the two different concentrations used for each pharmaceutical 









Figure 1. LC–HRMS extracted ion chromatogram of 29 target compounds from a full scan LC-3 





Figure 2. Heat map of triclosan exposure representing the fold change of targeted metabolites in each exposure subgroup (C1, C2) relative to controls. All data 6 
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Figure 3. Heat map of nimesulide exposure representing the fold change of targeted metabolites in each exposure subgroup (C1, C2) relative to controls. All 9 




  11 
Figure 4. Heat map of propranolol exposure representing the fold change of targeted metabolites in each exposure subgroup (C1, C2) relative to controls. All 12 
data have been auto scaled by column and dendrograms represent hierarchical analysis for clustering (A & B) of metabolite responses.  13 
